PACB News and Press, Pacific Biosciences of California Inc. From 01/13/23

PacBio Celebrates Nature Methods Naming Long-Read Sequencing "Method of the Year" PR Newswire MENLO PARK, Calif. , Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrate...

PacBio Announces Record Orders, Including Orders for 76 Revio Systems Received in the Fourth Quarter of 2022 PR Newswire PacBio also Releases Preliminary Fourth Quarter 2022 Revenue, Shares Positive Onso Beta Feedback, and Launches the PacBio Compatible Program M...

PacBio and the University of Tokyo Announce Bioinformatics Applications Collaboration PR Newswire MENLO PARK, Calif. , Jan. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of highly accurate sequencing solutions, today announced a collabora...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

Summary ARK Genomic Revolution ETF invests in small-cap and mid-cap companies engaged in genomic revolution, i.e., in the research of genomic sequencing, analysis, synthesis, or instrumentation. Alpha-generating stocks ARKG selects from time to time and backs for a longer time period ha...

Summary ARK Invest does great deep-dive research. Utilize their insights along with market timing considerations to generate alpha. The performance of ARKG is dictated mostly by interest rate decisions in the current environment. But underneath the macro layer, there are many promising ...

PacBio to Present at 41st Annual J.P. Morgan Healthcare Conference PR Newswire MENLO PARK, Calif. , Dec. 28, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will b...

Summary PacBio has recently introduced new products that are expected to drive strong growth and improve gross margins over the next four to five years. The new products are the materialization of the company’s long-read technology, and can unlock revenue growth and gross margins...

Summary Bionano Genomics, Inc. is an engaging company operating in the genome mapping space. The company generated $7.2m of revenues from 217 installed bases in Q322. Performance of genetic testing developers, e.g., Illumina and PacBio, in 2022 has been poor. Bionano is making b...

PacBio and Boston Children's Hospital Collaborate to Investigate Novel Variants Inaccessible by Short-Read Sequencing PR Newswire Researchers to Investigate Genetic Variants Associated with Rare Pediatric Diseases MENLO PARK, Calif. , Dec. 6, 2022 /PRNews...